- Amdocs reported an adjusted earnings per share (EPS) of $1.66 for the first quarter, surpassing the estimate of $1.64.
- Revenue for the first quarter was $1.11 billion, aligning with market estimates.
- For the second quarter, Amdocs forecasts adjusted EPS to range from $1.67 to $1.73, with the market estimate being $1.71.
- Projected revenue for the second quarter is between $1.11 billion and $1.15 billion, slightly above the estimated $1.12 billion.
- Analyst recommendations include 5 buys, 1 hold, and no sell ratings.
A look at Amdocs Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided a holistic view of Amdocs Ltd‘s long-term prospects based on their Smart Scores. Amdocs, a provider of information system solutions to telecommunications giants globally, has received solid scores across the board. With a balanced rating of 3 out of 5 for Value, Dividend, Growth, and Resilience, the company showcases stability and consistent performance in key areas. Additionally, boasting a score of 4 for Momentum, Amdocs demonstrates potential for upward growth and market momentum in the foreseeable future.
Amdocs Limited, a leader in integrated customer care and billing systems for major telecom operators, stands out as a well-rounded player in the industry. The company’s Smart Scores reflect a positive outlook, indicating a strong foundation and promising growth opportunities ahead. Amdocs’ focus on providing tailored solutions to meet the evolving needs of the telecommunications sector positions it favorably for sustained success in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
